Evidence map›Paper›PMID 33918136›Full record

ReviewCancers2021

Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs.

Sara Tomei, Ola Ibnaof, Shilpa Ravindran, Soldano Ferrone, Cristina Maccalli

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sara TomeiResearch Department, Sidra Medicine, Doha, Qatar.ORCID 0000-0001-5334-9140
Ola IbnaofResearch Department, Sidra Medicine, Doha, Qatar.
Shilpa RavindranResearch Department, Sidra Medicine, Doha, Qatar.
Soldano FerroneDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-2900-8834
Cristina MaccalliResearch Department, Sidra Medicine, Doha, Qatar.ORCID 0000-0002-6737-4715
Harvard University · US

Funding

T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancerR01DE028172 · NIDCR · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, XINHUI · 2018 to 2022
$1.9M
Adaptive immunotherapy of anaplastic thyroid cancerR03CA239193 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PARANGI, SAREH · 2019 to 2020
$165k
NCI NIH HHS R03 CA239193NIDCR NIH HHS R01 DE028172Qatar National Research Fund NPRP10-0129-170277
6 · The paper itself

Abstract

Cancer cells endowed with stemness properties and representing a rare population of cells within malignant lesions have been isolated from tumors with different histological origins. These cells, denominated as cancer stem cells (CSCs) or cancer initiating cells (CICs), are responsible for tumor initiation, progression and resistance to therapies, including immunotherapy. The dynamic crosstalk of CSCs/CICs with the tumor microenvironment orchestrates their fate and plasticity as well as their immunogenicity. CSCs/CICs, as observed in multiple studies, display either the aberrant expression of immunomodulatory molecules or suboptimal levels of molecules involved in antigen processing and presentation, leading to immune evasion. MicroRNAs (miRNAs) that can regulate either stemness properties or their immunological profile, with in some cases dual functions, can provide insights into these mechanisms and possible interventions to develop novel therapeutic strategies targeting CSCs/CICs and reverting their immunogenicity. In this review, we provide an overview of the immunoregulatory features of CSCs/CICs including miRNA profiles involved in the regulation of the interplay between stemness and immunological properties.

Indexed as

cancer stem cells/cancer initiating cellsimmune responsesimmunomodulating moleculesmicroRNAstumor microenvironment

Identifiers

PMID33918136
PMCPMC8037840
OpenAlexW3143872534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.